Associated Papers
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test.
Mansinho A et al.
Cancers, 2026
PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants.
Kohanbash G et al.
Research Square, 2026
Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.
Yamada S et al.
Brain Tumor Pathology, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.
Schoof M et al.
Nature Genetics, 2026
FGFR1 Mutations Are Rare Alternate Oncogenic Drivers in FOXL2 -Wildtype Adult Granulosa Cell Tumors of the Ovary.
Kolin DL et al.
The American Journal of Surgical Pathology, 2025
Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.
Boni J et al.
The Embo Journal, 2025
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.
Spanggaard I et al.
The Oncologist, 2025
Histopathologic Features and Molecular Markers of Encephalocraniocutaneous Lipomatosis (ECCL).
Venigalla S et al.
Dermatopathology (basel, Switzerland), 2025
FGFR1 Tyrosine Kinase Domain Variant p.Val561Met in Caudal Dysraphism: A Case Report.
Goel H et al.
Birth Defects Research, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Diffuse leptomeningeal glioneuronal tumour: molecular diagnosis, evolution and treatment.
Campanelli A et al.
Acta Neuropathologica Communications, 2025
Molecular Landscape of Pediatric Low-Grade Gliomas: Insights From RNA-NGS and Bioinformatic Analysis.
Brož P et al.
Genes, Chromosomes & Cancer, 2025
Encephalocraniocutaneous lipomatosis-a neuroradiological perspective.
Patel DD et al.
Pediatric Radiology, 2025
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
Miller AR et al.
Bmc Cancer, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Apfelbaum AA et al.
Nature Communications, 2025
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.
Hoskins EL et al.
Npj Precision Oncology, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
Morfouace M et al.
European Journal of Cancer (oxford, England : 1990), 2025
Case Series of Patients With FGFR1-Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options.
Jhawar S et al.
Clinical Endocrinology, 2025
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Ziegler M et al.
Jco Precision Oncology, 2025
Structural Insights Into the Impact of the Glycine-Rich Loop Mutation in Noonan Syndrome on the ATP Binding Pocket of CRAF Kinase.
Janati-Fard F et al.
Proteins, 2025
Diffuse astrocytoma, AYA-type, frequently MAPK-altered: report of 45 patients.
Singh O et al.
Acta Neuropathologica, 2025
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas.
Jokinen V et al.
Bjc Reports, 2025
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.
Fougner V et al.
Neuro-oncology Practice, 2025
Somatic DNA Variants in Epilepsy Surgery Brain Samples from Patients with Lesional Epilepsy.
Schwarz JM et al.
International Journal of Molecular Sciences, 2025
Insights into the genetic landscape of pheochromocytomas and paragangliomas in a Brazilian cohort.
Fagundes GFC et al.
European Journal of Endocrinology, 2025
Case Report: FGFR1 mutation and massive chromosome loss drive malignant transformation of low-grade gliomas.
Tang R et al.
Frontiers in Oncology, 2025
Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults.
Nunno VD et al.
Cns Oncology, 2024
Targeted DNA Sequencing in Diagnosis of Malignant Phyllodes Tumors With Emphasis on Tumors With Keratin and p63 Expression.
Ye J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
Genetic alteration analysis of non-pediatric diffuse midline glioma, H3 K27-altered.
Jang H et al.
Human Pathology, 2024
Fulminant leptomeningeal disease diagnosed as comutant H3F3A and FGFR diffuse midline glioma.
Benistant L et al.
Annals of Clinical and Translational Neurology, 2024
The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors.
Yang Z et al.
Biomedicines, 2024
A Hemorrhagic Brain Mass in a Child With Encephalocraniocutaneous Lipomatosis.
Hall E et al.
Journal of Pediatric Hematology/oncology, 2024